Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynecology,Oncology
Reference40 articles.
1. Made-to-measure medicine: BRCA and gynaecological cancer;Foulkes;Lancet Oncol.,2014
2. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nature,2005
3. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy;Haince;Trends Mol. Med.,2005
4. PARP inhibition: a promising therapeutic target in ovarian cancer;Musella;Cell Mol. Biol. (Noisy-le-grand),2015
5. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy;Kim;Clin. Cancer Res.,2015
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Assessing the antitumor effects of metformin on ovarian clear cell carcinoma;Human Cell;2024-08-08
2. Bidirectional pharmacokinetic drug interactions between olaparib and metformin;Cancer Chemotherapy and Pharmacology;2023-10-10
3. A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer;International Journal of Nanomedicine;2023-10
4. Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation;Translational Oncology;2022-02
5. Targeting the tumour microenvironment in platinum-resistant ovarian cancer;Seminars in Cancer Biology;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3